Copyright
©The Author(s) 1997.
World J Gastroenterol. Mar 15, 1997; 3(1): 43-46
Published online Mar 15, 1997. doi: 10.3748/wjg.v3.i1.43
Published online Mar 15, 1997. doi: 10.3748/wjg.v3.i1.43
Table 1 Pretreatment clinical characteristics of the treatment and control (A, B, C) groups
| Characteristics | Treatment group | Control groups | ||
| A | B | C | ||
| Cases | 22 | 25 | 21 | 25 |
| Sex (male/female) | 20/2 | 25/0 | 20/1 | 24/1 |
| Average age (yr) | 46.4 | 42.6 | 43.7 | 45.3 |
| Age range | 27.65 | 28.71 | 30.6 | 31.64 |
| Type, stage (II/III) | ||||
| Simple type (case) | 14/1 | 15/1 | 15/1 | 17/1 |
| Cirrhotic type (case) | 7/0 | 8/1 | 5/0 | 6/1 |
| Tumor mass ≤ 7 | 2 | 7 | 6 | 8 |
| Size (cm) 7.1 - 10 | 10 | 13 | 8 | 13 |
| > 10 | 10 | 5 | 7 | 4 |
| Node single | 9 | 12 | 6 | 16 |
| multiple | 13 | 13 | 15 | 9 |
| Portal vein tumor thrombus | 9 | 11 | 6 | 9 |
| AFP > 400 (μg/L) | 20 | 25 | 21 | 18 |
| < 25 | 2 | 0 | 0 | 7 |
| HBsAg (+) | 19 | 21 | 18 | 22 |
- Citation: Wu YD, Yang KZ, Zhou DN, Gang YQ, Song XQ, Hu XH, Huang BY. Clinical observation of 125I-labeled anti-alpha fetoprotein antibody radioimmunotherapy in hepatocellular carcinoma. World J Gastroenterol 1997; 3(1): 43-46
- URL: https://www.wjgnet.com/1007-9327/full/v3/i1/43.htm
- DOI: https://dx.doi.org/10.3748/wjg.v3.i1.43